Updates are available Correction dated 2024-09-04

Article History

Received: 21 March 2024

Revised: 29 April 2024

Accepted: 30 April 2024

First Online: 21 May 2024

Change Date: 4 September 2024

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s00415-024-12628-2

Declarations

:

: Paolo Preziosa received speaker honoraria from Roche, Biogen, Novartis, Merck Serono, Bristol Myers Squibb and Sanofi; he has received research support from Italian Ministry of Health and Fondazione Italiana Sclerosi Multipla. Maria Pia Amato has served on Scientific Advisory Boards for Biogen, Novartis, Roche, Merck, Sanofi Genzyme and Teva; has received speaker honoraria from Biogen, Merck, Sanofi Genzyme, Roche, Novartis and Teva; has received research grants for her Institution from Biogen, Merck, Sanofi Genzyme, Novartis and Roche. She is co-Editor of the Multiple Sclerosis Journal and Associate Editor of Frontiers in Neurology. Luca Battistini has served on Scientific Advisory Boards or has given advice to Horizon, Merck, Roche, Teva, Novartis, Bristol Myers Squibb, GSK, and Sanofi-Genzyme; has received speaker honoraria from Horizon, Janssen, Baxter, Merck, Roche, Teva, Biogen, Novartis, Bristol Myers Squibb, GSK, and Sanofi-Genzyme; his preclinical and clinical research was supported by grants from Baxter, Merck, Roche, Teva, Celgene and Sanofi-Genzyme; he has also received research support from Italian Ministry of Health and Fondazione Italiana Sclerosi Multipla. Marco Capobianco received personal compensation for consulting from Alexion, Biogen, Roche, Novartis, Sanofi, and Merck; research grant from Roche, Novartis and FISM. Diego Centonze is an Advisory Board member or has given advice to Almirall, Bayer Schering, Biogen, GW Pharmaceuticals, Merck Serono, Novartis, Roche, Sanofi-Genzyme, and Teva; has received honoraria for speaking or consultation fees from Almirall, Bayer Schering, Biogen, GW Pharmaceuticals, Merck Serono, Novartis, Roche, Sanofi-Genzyme, and Teva; is the principal investigator in clinical trials for Bayer Schering, Biogen, Merck Serono, Mitsubishi, Novartis, Roche, Sanofi-Genzyme, and Teva. His preclinical and clinical research was supported by grants from Bayer Schering, Biogen Idec, Celgene, Merck Serono, Novartis, Roche, Sanofi-Genzyme and Teva. Eleonora Cocco received personal compensation for consulting and speaker fees from Alexion, Biogen, BMS, Janssen, Merck, Novartis, Roche, and Sanofi. Antonella Conte received consulting research funding from Novartis, Roche, Biogen, Merck Serono, and Almirall. Claudio Gasperini has served on Scientific Advisory Boards for Biogen, Novartis, Roche, Merck, Sanofi Genzyme; has received speaker honoraria from Biogen, Merck, Bayer, Sanofi Genzyme, Roche, Novartis, Almirall, Mylan. Matteo Gastaldi received compensation for speaking activities and/or consulting services, from Alexion, UCB, and Roche. Carla Tortorella received travel funding and/or speaker honoraria from Alexion, Almirall, Biogen, Horizon, Merck, Novartis, Roche, Sanofi. Massimo Filippi is Editor-in-Chief of the <i>Journal of Neurology</i>, Associate Editor of <i>Human Brain Mapping</i>, <i>Neurological Sciences,</i> and <i>Radiology</i>; received compensation for consulting services from Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi; speaking activities from Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and TEVA; participation in Advisory Boards for Alexion, Biogen, Bristol-Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi-Genzyme, Takeda; scientific direction of educational events for Biogen, Merck, Roche, Celgene, Bristol-Myers Squibb, Lilly, Novartis, Sanofi-Genzyme; he receives research support from Biogen Idec, Merck-Serono, Novartis, Roche, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.

: Not applicable.